By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board. Novo, the drugmaker behind blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic, launched a bid on Thursday for Metsera valuing the firm at some $9 billion and crashing Pfizer's deal for the firm announced in September. The move, after No ...